Kala BIO, Inc.

KALA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001479419


None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $9.5M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, short runway, late filer, thin...
Inputs computable	6 of 14
Graded from	filings received through Apr 15, 2026 215 days before the rescan; latest periodic filing 10-Q received Aug 19, 2026
Last close	$0.14 2026-11-13; market equity $79.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Apr 15, 2026

In this Annual Report on Form 10-K, unless the context otherwise requires, references to "we," "us," "our," "our company," "KALA," "KALA BIO" and "Company" refer to KALA BIO, Inc. and its subsidiaries. We are a biopharmaceutical company in transition, evaluating the development of a dedicated, on-premises artificial intelligence (AI) infrastructure platform for the biotechnology industry. Our current focus is leveraging our mesenchymal stem cell secretome ("MSC-S") platform to test development of a scalable AI platform-as-a-service business to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 93.9						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	15.4%	(6.6%)	93.9	799	2025-12-31	
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 78.7						
Twelve-month failure probability	4.84%	0.08%	89.3	245	2026-06-30	
Altman Z double-prime	(258.66)	(0.31)	99.1	743	2025-12-31	
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	3.81x	2.96x	47.6	825	2025-12-31	
Growth and financing, sleeve percentile 99.0						
Revenue growth, three-year compound	not computable	10.1%				
current value must be positive and the base must exceed $100,000						
Free cash flow growth, three-year compound	not computable	11.0%				
four consecutive annual FCF observations are required; found 3						
Reinvestment rate	not computable	37.1%				
one or more required annual facts are missing						
Asset growth, three years	(52.2%)	2.3%	98.4	693	2025-12-31	
Net share issuance, one year	14,305.4%	2.4%	99.5	627	2026-04-10	

Warnings

7 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 14305.4%
Short runway	cash runway is 0.1 months
Late filer	found 4 NT 10-K/Q filings in the last eight quarters
Thin data	6 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor
Distress	CHS probability 4.836005%; universe top-decile threshold 3.220766%
Fortress balance sheet	cash minus debt is 27,192,000 USD; Altman Z is not used

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(98.9%)	(1.5%)	0
Distance from 52-week high	(93.7%)	(32.0%)	3
EBIT to enterprise value	(36.5%)	(1.8%)	17
Free cash flow yield	(116.8%)	(1.0%)	7
Book value to price	0.11	0.29	26
Sales to price	0.00	0.29	0
Composite equity issuance, five years	666.6%	19.1%	98
Relative strength against the sector, log excess return	(4.68)	(0.18)	0

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on assets improved	pass
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$229,000
Operating cash flow, four quarters	-$19.9M
Months of runway	0.1
Days since last periodic filing	89 (10-Q received Aug 19, 2026)
Median daily dollar volume, 63 sessions	$71,188

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$27.0M	2025-12-31	2026-04-15	10-K	26-043782
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$32.0M	2025-12-31	2026-04-15	10-K	26-043782
3	assets	us-gaap:Assets	$9.5M	2025-12-31	2026-04-15	10-K	26-043782
4	assets	us-gaap:Assets	$55.5M	2024-12-31	2026-04-15	10-K	26-043782
5	current assets	us-gaap:AssetsCurrent	$9.5M	2025-12-31	2026-04-15	10-K	26-043782
6	current liabilities	us-gaap:LiabilitiesCurrent	$2.5M	2025-12-31	2026-04-15	10-K	26-043782
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$694.9M	2025-12-31	2026-04-15	10-K	26-043782
8	operating income	us-gaap:OperatingIncomeLoss	-$39.2M	2025-12-31	2026-04-15	10-K	26-043782
9	book equity	us-gaap:StockholdersEquity	$7.0M	2025-12-31	2026-04-15	10-K	26-043782
10	liabilities	us-gaap:Liabilities	$2.5M	2025-12-31	2026-04-15	10-K	26-043782
11	total debt	us-gaap:LongTermDebt	$43.3M	2022-12-31	2023-03-03	10-K	23-002746
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$70.5M	2022-12-31	2024-03-29	10-K	24-004326
13	operating income	us-gaap:OperatingIncomeLoss	-$81.7M	2022-12-31	2024-03-29	10-K	24-004326
14	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$537,000	2022-12-31	2024-03-29	10-K	24-004326
15	operating income	us-gaap:OperatingIncomeLoss	-$39.7M	2023-12-31	2025-03-31	10-K	25-004081
16	interest expense	us-gaap:InterestExpense	$5.8M	2023-12-31	2024-03-29	10-K	24-004326
17	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$0	2025-12-31	2026-04-15	10-K	26-043782
18	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$0	2024-12-31	2026-04-15	10-K	26-043782
19	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$0	2023-12-31	2025-03-31	10-K	25-004081
20	revenue	us-gaap:RevenueFromContractWithCustomerIncludingAs...	$3.9M	2022-12-31	2024-03-29	10-K	24-004326
21	assets	us-gaap:Assets	$55.9M	2023-12-31	2025-03-31	10-K	25-004081
22	assets	us-gaap:Assets	$86.8M	2022-12-31	2024-03-29	10-K	24-004326
23	shares outstanding	dei:EntityCommonStockSharesOutstanding	929,491,578	2026-04-10	2026-04-15	10-K	26-043782
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	6,452,398	2025-03-28	2025-03-31	10-K	25-004081

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.